51 results
10-K
2022 FY
EX-10.20
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
Party shall reasonably cooperate with the Indemnifying Party’s investigation by giving such information and assistance (including the right to examine … and investigation of the Third-Party Claim, with counsel reasonably acceptable to the Indemnified Party, and the Indemnified Party shall fully cooperate
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
on their www.clinicaltrials.gov website.
Companies generally divide the clinical investigation of a drug into three or four phases. While companies … on the significance of the change, it may require prior FDA approval before we can implement it. FDA regulations also require investigation
F-3
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
. This limitation does not apply to proposals to convene an extraordinary general meeting of shareholders or to initiate a special investigation … of our business secrets. See “Comparison of Swiss Law and Delaware Law—Inspection of Books and Records.”
Special Investigation
If the shareholders
F-3
EX-4.2
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
it by this Indenture;
(f) The Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate … of such investigation is, in the opinion of the Trustee, not reasonably assured to the Trustee by the security afforded to it by the terms of this Indenture
6-K
EX-99.3
krkmpag7
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
6-K/A
EX-99.2
kxlli8owbro0sm6
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K/A
EX-99.5
mukr10ggmrkh5sp
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
EX-99.5
fbg10wc19nt
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.2
jn8wxawwzfl4sb3pk5v
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.2
ek80b7mo rja28
1 Jun 21
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
6:30am
6-K
EX-99.1
48163rg soldl7
31 Mar 21
Current report (foreign)
7:15am
6-K
EX-1.1
wsym0lv5u0 n680ep
5 Mar 21
Current report (foreign)
8:15am
424B5
2y0su6te0 tymq07osu
5 Mar 21
Prospectus supplement for primary offering
7:55am
6-K
EX-99.2
nto 7peae
17 Feb 21
ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference
6:04am